Traws Pharma Inc. reported completion of its clinical analysis from a 90-patient, open-label Phase 2 study evaluating ratutrelvir, an investigational oral ritonavir-free Mpro/3CL protease inhibitor, versus PAXLOVID in mild-to-moderate COVID-19 patients, including a separate single-arm cohort of PAXLOVID-ineligible patients. The company said the analysis found fewer treatment-related adverse events and no viral rebound events in ratutrelvir-treated patients, with equivalent time to sustained symptom resolution versus PAXLOVID; in PAXLOVID-ineligible patients, it reported a shorter time to symptom resolution compared with PAXLOVID. The company also provided preclinical and development updates on tivoxavir marboxil tablets for once-monthly influenza prophylaxis, including plans for a PK study under an open IND in Australia and preparations for a human influenza prophylaxis challenge study in the UK. The ratutrelvir results were presented as completed in the announcement; no future presentation date was specified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9657427-en) on February 19, 2026, and is solely responsible for the information contained therein.